These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29217423)

  • 21. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome.
    Reinsmoen NL; Lai CH; Mirocha J; Cao K; Ong G; Naim M; Wang Q; Haas M; Rafiei M; Czer L; Patel J; Kobashigawa J
    Transplantation; 2014 Mar; 97(5):595-601. PubMed ID: 24162250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute kidney transplant rejection mediated by angiotensin II type 1 receptor antibodies in a pediatric hyperimmune patient.
    Guzzo I; Morolli F; Camassei FD; Piazza A; Poggi E; Dello Strologo L
    Pediatr Nephrol; 2017 Jan; 32(1):185-188. PubMed ID: 27752765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study.
    Deltombe C; Gillaizeau F; Anglicheau D; Morelon E; Trébern-Launay K; Le Borgne F; Rimbert M; Guérif P; Malard-Castagnet S; Foucher Y; Giral M
    Transpl Int; 2017 Nov; 30(11):1150-1160. PubMed ID: 28686316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.
    Giral M; Foucher Y; Dufay A; Duong Van Huyen JP; Renaudin K; Moreau A; Philippe A; Hegner B; Dechend R; Heidecke H; Brouard S; Cesbron A; Castagnet S; Devys A; Soulillou JP; Dragun D
    Am J Transplant; 2013 Oct; 13(10):2567-76. PubMed ID: 23919486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients.
    O'Leary JG; Philippe A; Freeman R; Heidecke H; Jennings LW; Catar R; Klintmalm GB; Dragun D
    Transplant Proc; 2021 Apr; 53(3):1019-1024. PubMed ID: 33579550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of positive pre-transplant angiotensin II type 1 receptor antibodies with clinical outcomes in lung transplant recipients.
    Son BS; Lee HJ; Cho WH; So MW; Park JM; Yeo HJ
    Transpl Immunol; 2023 Oct; 80():101901. PubMed ID: 37442212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The early impact of preformed angiotensin II type 1 receptor antibodies on graft function in a low immunological risk cohort of kidney transplant recipients.
    Sorohan BM; Ismail G; Berechet A; Obrișcă B; Constantinescu I; Mărunțelu I; Tacu D; Baston C; Sinescu I
    Transpl Immunol; 2021 Jun; 66():101389. PubMed ID: 33838295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
    Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
    Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rejection and graft outcomes in kidney transplant recipients with and without angiotensin II receptor type 1 antibodies.
    Aljishi M; Isbel NM; Jegatheesan D; Johnson DW; Cho Y; Campbell SB; Hawley CM; Thornton A; Gillis D; Johnstone K
    Transpl Immunol; 2023 Feb; 76():101756. PubMed ID: 36460263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II Type 1 Receptor Expression in Renal Transplant Biopsies and Anti-AT1R Antibodies in Serum Indicates the Risk of Transplant Loss.
    Sas-Strózik A; Donizy P; Kościelska-Kasprzak K; Kamińska D; Gawlik K; Mazanowska O; Madziarska K; Hałoń A; Krajewska M; Banasik M
    Transplant Proc; 2020 Oct; 52(8):2299-2304. PubMed ID: 32448653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-HLA Antibodies May Accelerate Immune Responses After Intestinal and Multivisceral Transplantation.
    Gerlach UA; Lachmann N; Ranucci G; Sawitzki B; Schoenemann C; Pratschke J; Dragun D; Pascher A
    Transplantation; 2017 Jan; 101(1):141-149. PubMed ID: 27495766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes.
    Banasik M; Boratyńska M; Kościelska-Kasprzak K; Krajewska M; Mazanowska O; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Dawiskiba T; Chudoba P; Klinger M
    Transpl Immunol; 2014 Jan; 30(1):24-9. PubMed ID: 24184747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation.
    Hiemann NE; Meyer R; Wellnhofer E; Schoenemann C; Heidecke H; Lachmann N; Hetzer R; Dragun D
    Transplantation; 2012 Nov; 94(9):919-24. PubMed ID: 23034559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of anti-angiotensin II type 1 receptor antibodies on the outcomes of kidney transplantation: a systematic review and meta-analysis.
    Kang ZY; Liu C; Liu W; Li DH
    Nephrol Dial Transplant; 2022 May; 37(6):1171-1180. PubMed ID: 34865146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years.
    Aziz F; Jung-Hynes B; Parajuli S; Redfield RR; Astor BC; Mandelbrot D; Hidalgo L; Djamali A
    Clin Nephrol; 2020 Nov; 94(5):245-251. PubMed ID: 32870149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies.
    Pearl MH; Leuchter RK; Reed EF; Zhang Q; Ettenger RB; Tsai EW
    Pediatr Nephrol; 2015 Aug; 30(8):1371-4. PubMed ID: 25956702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical conundrums in pediatric kidney transplantation: What we know about the role of angiotensin II type I receptor antibodies in pediatric kidney transplantation and the path forward.
    Pearl MH
    Pediatr Transplant; 2024 May; 28(3):e14762. PubMed ID: 38650537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney re-transplantation in a child across the barrier of persisting angiotensin II type I receptor antibodies.
    Gold A; Fichtner A; Choukair D; Schmitt CP; Süsal C; Dragun D; Tönshoff B
    Pediatr Nephrol; 2021 Mar; 36(3):725-729. PubMed ID: 33355703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.